Impact Factor
4.65
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
16.68
7,834 total citations
h5-index
130
h5 depth signal
Cited share
64.3%
314 of 488
Total citations
7,834
Citation footprint
Metric signal
16.35
External metric anchor
Self-citation
0.5%
39 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
464
United Kingdom
172
Germany
91
Switzerland
77
France
52
Citing Fields of Research
Immunology
403
Oncology
343
Medical Ethics
342
Cancer Drugs
263
Pharmacology & Toxicology
230
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
6,742
Articles tracked across the journal lifetime
Indexed publication set
488
314 cited publications
Last 12 months
240
20.0 publications/month
Open access share
0.4%
1 OA publications in the last year
Leading citing country
United States
464 citing publications
Leading citing field
Immunology
403 citing publications
Latest tracked publication
16 October 2026
10 recent records available
Coverage & Indexing History
v1n1, Jan. 2002-
v1n1, Jan. 2002-
Active Coverage
Research Focus & Classification
Indexed Subjects
Immunology
Medical Ethics
Oncology
Cancer, Autophagy & Apoptosis
Pharmacology & Toxicology
Immunotherapy
Broad Categories
Drug Therapy
Pharmacology
Medical Ethics
Immunotherapy
Nucleic Acids Chemistry
Immunology
Hematology
Musculoskeletal Disorders
MeSH Descriptors
Pharmaceutical Preparations
Research
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1038/s41573-026-01548-7
Open DOI
Translating base editors: a decade of progress from the bench to the clinic
A decade has passed since the initial description of cytosine base editors in 2016. This new class of gene editors, utilizing DNA damage intermediates beyond double-stranded DNA breaks, fundamentally shifted the paradigm of gene editing ...
02
DOI 10.1038/d41573-026-00165-8
Open DOI
One year of Commissioner’s National Priority Vouchers
03
DOI 10.1038/d41573-026-00164-9
Open DOI
FDA new drug approvals in Q3 2026
04
DOI 10.1038/d41573-026-00163-w
Open DOI
Molecular glue targets ALK resistance
05
DOI 10.1038/s41573-026-01534-z
Open DOI
Next-generation immune cell engagers for B cell depletion in autoimmune diseases
06
DOI 10.1038/d41573-026-00161-y
Open DOI
Probing the many benefits of GLP-1 receptor agonists
07
DOI 10.1038/d41573-026-00160-z
Open DOI
Gene therapy for rare lysosomal storage disorder nabs FDA approval
08
DOI 10.1038/d41573-026-00162-x
Open DOI
COPD trial wins spur broad respiratory hopes
09
DOI 10.1038/s41573-026-01535-y
Open DOI
Soft drugs: design principles and topical applications
The rational design of soft drugs has emerged as a powerful strategy to enhance drug safety, without compromising efficacy. Unlike conventional active pharmaceutical ingredients, soft drugs are deliberately designed to undergo predictabl...
10
DOI 10.1038/s41573-026-01531-2
Open DOI
The cellular landscape of druggable RNA-binding proteins
Bibliographical & Catalog Notes
Title from cover.
Also issued online.